Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimism in IBM
NCT04789070Phase 3Active, not recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Jul 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in inclusion body myositis (IBM) comparing Sirolimus with Placebo (2 arms). Primary endpoint: IBM Functional Rating Scale at 84 weeks. Started Jul 2022; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT04789070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789070.